These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 31669398)

  • 1. Late Events After CD-19 CAR-T Treatment.
    Hossain NM; Nishimura MI
    Biol Blood Marrow Transplant; 2020 Jan; 26(1):e1-e2. PubMed ID: 31669398
    [No Abstract]   [Full Text] [Related]  

  • 2. Trafficking of CAR T cells to sites of subclinical leukaemia cutis.
    O'Reilly M; Roddie C; Marzolini MAV; Rodriguez-Justo M; Pomplun S; Pule M; Peggs KS
    Lancet Oncol; 2020 Mar; 21(3):e179. PubMed ID: 32135121
    [No Abstract]   [Full Text] [Related]  

  • 3. CAR T-cells for relapsed B-cell ALL in adults.
    Gilbert JA
    Lancet Oncol; 2018 Mar; 19(3):e143. PubMed ID: 29429915
    [No Abstract]   [Full Text] [Related]  

  • 4. Donor origin CAR19 T cell infusion for B-ALL relapsed after allogeneic hematopoietic stem cell transplantation.
    Yang X; Dai H; Kang L; Qu C; Li Z; Yin J; Qiu H; Fu C; Han Y; Jin Z; Ma X; Zhu X; Yu L; Wu D; Tang X
    Hematol Oncol; 2019 Dec; 37(5):655-658. PubMed ID: 31656047
    [No Abstract]   [Full Text] [Related]  

  • 5. Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma.
    Chow VA; Shadman M; Gopal AK
    Blood; 2018 Aug; 132(8):777-781. PubMed ID: 29914976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy.
    Chow VA; Gopal AK; Maloney DG; Turtle CJ; Smith SD; Ujjani CS; Shadman M; Cassaday RD; Till BG; Tseng YD; Warren EH; Shustov AR; Menon MP; Bhark S; Acharya UH; Mullane E; Hannan LM; Voutsinas JM; Gooley TA; Lynch RC
    Am J Hematol; 2019 Aug; 94(8):E209-E213. PubMed ID: 31056762
    [No Abstract]   [Full Text] [Related]  

  • 7. CAR T-cells for relapsed B-cell ALL in children and young adults.
    Stirrups R
    Lancet Oncol; 2018 Mar; 19(3):e144. PubMed ID: 29429913
    [No Abstract]   [Full Text] [Related]  

  • 8. CD19 CAR-T Cells With Membrane-Bound IL-15 for B-Cell Acute Lymphoblastic Leukemia After Failure of CD19 and CD22 CAR-T Cells: Case Report.
    Sun Y; Su Y; Wang Y; Liu N; Li Y; Chen J; Qiao Z; Niu J; Hu J; Zhang B; Ning H; Hu L
    Front Immunol; 2021; 12():728962. PubMed ID: 34691036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Success of donor-derived CAR-T cells after failure of autologous CD19 CAR-T cells (tisagenlecleucel) in B-cell acute lymphoblastic leukaemia.
    Dourthe ME; Yakouben K; David A; Thouvenin S; Chaillou D; Caillat-Zucman S; Cuffel A; Tardy C; Lainey E; Caye-Eude A; Arfeuille C; Delaugerre C; Chaix-Baudier ML; Naudin J; Auvin S; Bergaoui K; Merlat-Guitard AI; De Jorna R; Mebarki M; Dalle JH; Baruchel A
    Br J Haematol; 2024 Jul; 205(1):373-377. PubMed ID: 38735758
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment and outcomes of patients with B-ALL relapse after CD19 CAR-T therapy.
    Wang Y; Xue YJ; Zuo YX; Jia YP; Lu AD; Zeng HM; Zhang LP
    J Transl Med; 2024 Jul; 22(1):680. PubMed ID: 39061064
    [No Abstract]   [Full Text] [Related]  

  • 11. CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy.
    Pillai V; Muralidharan K; Meng W; Bagashev A; Oldridge DA; Rosenthal J; Van Arnam J; Melenhorst JJ; Mohan D; DiNofia AM; Luo M; Cherian S; Fromm JR; Wertheim G; Thomas-Tikhonenko A; Paessler M; June CH; Luning Prak ET; Bhoj VG; Grupp SA; Maude SL; Rheingold SR
    Blood Adv; 2019 Nov; 3(22):3539-3549. PubMed ID: 31738832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An analytical biomarker for treatment of patients with recurrent B-ALL after remission induced by infusion of anti-CD19 chimeric antigen receptor T (CAR-T) cells.
    Zhang Y; Zhang W; Dai H; Wang Y; Shi F; Wang C; Guo Y; Liu Y; Chen M; Feng K; Zhang Y; Liu C; Yang Q; Li S; Han W
    Sci China Life Sci; 2016 Apr; 59(4):379-85. PubMed ID: 27009300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeric Antigen Receptor Therapy in Acute Lymphoblastic Leukemia Clinical Practice.
    Luskin MR; DeAngelo DJ
    Curr Hematol Malig Rep; 2017 Aug; 12(4):370-379. PubMed ID: 28656487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.
    Pehlivan KC; Duncan BB; Lee DW
    Curr Hematol Malig Rep; 2018 Oct; 13(5):396-406. PubMed ID: 30120708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CAR T-cell therapy in refractory large B-cell lymphoma.
    Stirrups R
    Lancet Oncol; 2018 Jan; 19(1):e19. PubMed ID: 29249304
    [No Abstract]   [Full Text] [Related]  

  • 16. Allogeneic CD19/CD22 CAR T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia.
    Phely L; Hensen L; Faul C; Ruff CA; Schneider D; Bethge WA; Lengerke C
    JAMA Oncol; 2024 Jun; 10(6):821-824. PubMed ID: 38635232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Open access? Widening access to chimeric antigen receptor (CAR) therapy for ALL.
    Ghorashian S; Amrolia P; Veys P
    Exp Hematol; 2018 Oct; 66():5-16. PubMed ID: 30031849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances in CAR-T cell engineering.
    ; ; . PubMed ID: 32616000
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.